NCT01290965已完成1 期
A Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics, and Effect of Treatment With SCY 635 on Plasma HCV RNA Following 15 Days of Oral Administration in Adult Patients With Chronic Hepatitis C Infection
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 57
- 试验地点
- 2
- 主要终点
- Incidence and severity of treatment-emergent adverse events and changes in laboratory values as measures of safety and tolerability.
研究概览
简要总结
This study will examine the effectiveness of 15 days of therapy with SCY-635 in reducing hepatitis C virus (HCV) RNA levels.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •A potential subject will be eligible for participation in this study if he or she meets all of the following inclusion criteria:
- •The subject is either male or female, between the ages of 18 and 65 years (inclusive).
- •The subject has read and signed a Subject Informed Consent form to participate in the study. If the subject is not fluent in English, the Subject Informed Consent form must be translated into his or her native language.
- •Female subjects of childbearing potential (i.e., women not surgically sterile or at least two years postmenopausal) must agree to utilize one of the following forms of contraception from Screening through completion of the study: abstinence, barrier (condom, diaphragm with spermicide), intrauterine device (IUD), or vasectomized partner (six months minimum). Hormonal contraception (oral, transdermal, implant, or injection) is not permitted during the study period (i.e., from Screening through the Follow-up visit). Note: For women aged <50 years, postmenopausal is defined as at least two years cessation of menses. For women aged ≥50 years, postmenopausal is defined as at least one year cessation of menses. Estrogen replacement is allowed during the study.
- •The subject exhibits quantifiable plasma levels of HCV-specific RNA in excess of 100,000 IU/mL as determined by the quantitative Roche COBAS taqMan assay.
- •The subject has a negative urine screen for amphetamines, barbiturates, cocaine, opiates, and phencyclidine at Screening.
- •If female, the subject has a negative serum pregnancy test at Screening (within 30 days prior to dosing) and a negative urine pregnancy test on Study Day -1.
排除标准
- •A potential subject will be excluded from participation in the study if he or she meets any of the following exclusion criteria:
- •The subject has a history of clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or cardiovascular disease, or any other condition which, in the opinion of the Principal Investigator, may jeopardize the safety of the subject or may impact the validity of the study results.
- •The subject is infected with any HCV genotype other than genotype
- •The subject has documented positive antibody tests for Human Immunodeficiency Virus Types 1 or 2 (p24 antibody specific for HIV-1 or HIV-2) or Hepatitis B virus (HBV) surface antigen (HbSAg) or at Screening exhibits serologic evidence of infection with either HIV-1, HIV-2 or HBV.
- •The subject has donated blood within 30 days prior to dosing or donated plasma within 14 days prior to dosing.
- •The subject has used any investigational agent within three months prior to dosing.
- •The subject has received any FDA-approved anti-HCV therapy (including ribavirin or any product that contains interferon) within three months prior to dosing.
- •The subject exhibits evidence of decompensated liver disease, as marked by bilirubin greater than 4 mg/dL, albumin less than 3.0 g/dL, prothrombin time greater than 2 seconds prolonged, or history of bleeding esophageal varices, ascites or hepatic encephalopathy.
- •The subject is an organ transplant recipient.
- •The subject exhibits ALT values greater than or equal to 2.5 times the upper limit of normal.
- •The subject exhibits evidence of hepatocellular carcinoma either by exhibiting a serum alpha-fetoprotein concentration which exceeds 50 mg/L or by exhibiting a mass suggestive of liver cancer by ultrasound or other imaging technology.
- •The subject exhibits evidence of ongoing alcohol or substance abuse.
研究组 & 干预措施
SCY-635 100 mg three times daily
Active Comparator
干预措施: SCY-635 (Drug)
Placebo comparator
Placebo Comparator
干预措施: Placebo (Drug)
SCY-635 30 mg once daily
Active Comparator
干预措施: SCY-635 (Drug)
SCY-635 100 mg once daily
Active Comparator
干预措施: SCY-635 (Drug)
SCY-635 300 mg once daily
Active Comparator
干预措施: SCY-635 (Drug)
SCY-635 200 mg three times daily
Active Comparator
干预措施: SCY-635 (Drug)
SCY-635 300 mg three times daily
Active Comparator
干预措施: SCY-635 (Drug)
结局指标
主要结局
Incidence and severity of treatment-emergent adverse events and changes in laboratory values as measures of safety and tolerability.
时间窗: 22 days
Plasma HCV RNA level
时间窗: 22 days
次要结局
- Pharmacokinetic assessment of SCY-635(22 days)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
A Study of TMC435350 Administered With or Without Standard of Care Therapy in Participants With Genotype 1 Hepatitis C Virus InfectionHepatitis C, ChronicNCT00561353Tibotec Pharmaceuticals, Ireland121
已完成
1 期
Staged Phase I/II Hepatitis C Prophylactic VaccineHepatitis CNCT01436357National Institute of Allergy and Infectious Diseases (NIAID)548
已完成
4 期
Maraviroc Efficacy for Hepatitis CHuman Immunodeficiency VirusHepatitis CNCT02881762University of Maryland, Baltimore10
已完成
3 期
Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection.Hepatitis CNCT02625909Kirby Institute222
已完成
4 期
A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3Hepatitis C, ChronicNCT01364090Kirby Institute93